Impel Pharmaceuticals Inc.
Impel Pharmaceuticals Inc. (IMPL) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
impl · stock forecast · 3 analysts (3M) · FMP · updated Mar 26, 2024
Analyst Rating & Consensus
Based on 3 Wall Street analysts in the past 3 months
Buy
3 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.10
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.10 | ↑ 0.00% |
1-day model range: $0.1–$0.1. Peak: $0.1 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · IMPL · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2022-11-15 | Wedbush | Downgrade ↓ | Outperform→Neutral |
| 2022-11-14 | Wedbush | Downgrade ↓ | Outperform→Neutral |
| 2022-08-25 | JonesTrading | Maintains | Buy→Buy |
| 2021-05-18 | Wedbush | Maintains | Outperform→Outperform |
| 2021-05-18 | Guggenheim | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Impel Pharmaceuticals Inc. (IMPL) stock. Of the recent 5 rating actions, 0 were upgrades and 2 were downgrades. 3 analysts currently cover IMPL.
Analyst Recommendation Trends
IMPL analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$2M
↓ 93.7% YoY
Revenue Next Year
$13M
↑ 602.9% YoY
EPS This Year
$-1.34
EPS Next Year
$-4.12
↑ 207.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast IMPL EPS of $-1.34 for the current fiscal year, based on estimates from 0 analysts. The IMPL revenue forecast is $2M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The IMPL stock forecast is supported by two independent data sources: analyst consensus ratings from 3 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus IMPL price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The IMPL short-term stock prediction for tomorrow is $0.10 (+0.00%).
Impel Pharmaceuticals Inc. trades on NASDAQ under the ticker IMPL. The IMPL stock outlook for 2027 is broadly positive, supported by a Buy consensus among 67% of covering analysts.
Frequently asked questions
IMPL forecast · 8 questionsAccording to 3 Wall Street analysts, the average 12-month IMPL price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.10.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.